(Getty/FamVeld)
As it awaits FDA feedback on its pivotal trial for its leading med, Minovia Therapeutics has hired Alan Jacobs, M.D., Ph.D., to help boost it over the line.
The U.S.-Israel biotech, which uses a platform to augment disease caused by mitochondrial dysfunction, will now tap Jacobs’ 20 years’ experience at companies including Aspire Health Science, Hemostemix and PerceptiMed.
As CMO, he will now lead Minovia’s clinical operations and regulatory affairs, including speeding up the development plans for Pearson Syndrome and other “primary and secondary mitochondrial diseases,” the biotech said in a statement.
Currently, Minovia is working on an IND-enabled phase 1/2 test in Pearson syndrome, a fatal pediatric disease. It hopes that by harnessing the power of mitochondria, membrane-bound cell organelles that generate most of the chemical energy needed to power the cell s biochemical reactions, it can help address this unmet medical need and hit other